Abstract
� Acquired Glanzmann thrombasthenia (GT) is a rare hemorrhagic disorder characterized by the impairment of platelet function caused by inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa) signaling, often by an autoantibody. This disorder has been associated with lymphoproliferative and autoimmune disease. � This report presents a case of a 44-year-old man with severe spontaneous bleeding associated with an antibody-mediated platelet aggregation defect in the setting of a newly diagnosed stage IVB classical Hodgkin lymphoma. The bleeding resolved immediately after ABVD (Adriamycin [doxorubicin]/bleomycin/ vinblastine/dacarbazine) chemotherapy with normalization of platelet aggregation studies. No steroids or other immunosuppressive therapies directed at the antiplatelet antibody were required. � This case shows that chemotherapy directed at underlying Hodgkin lymphoma can promptly resolve bleeding diathesis in acquired GT, although the antiplatelet antibody may persist.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
